FDA Clears Retia Medical's Cardiac Monitor

- The Argos Infinity™ is a software platform that analyzes real-time data from existing patient monitoring systems, eliminating the need for additional bedside hardware. It is built on Retia's Multi-Beat Analysis (MBA®) algorithm, which was originally developed at MIT and Michigan State University. - This clearance is timely as it addresses a key clinical concern: the early detection of hemodynamic instability. In cardiac surgery patients, for example, nearly 70% of the time when the cardiac index is low, the patient's blood pressure remains in the normal range. - The global market for cardiac output monitoring devices was valued at approximately USD 1.20 billion in 2021 and is projected to reach over USD 2.1 billion by 2030. This growth is driven by the rising prevalence of cardiovascular diseases and an aging global population. - Retia Medical's system is considered less invasive than traditional methods like the pulmonary artery catheter, which is often considered the gold standard but carries more risks. The market is seeing a trend towards minimally invasive and non-invasive monitoring solutions. - The 510(k) clearance from the FDA signifies that the Argos Infinity™ is "substantially equivalent" to a legally marketed device (a predicate device) that is not subject to premarket approval. - Retia Medical, founded in 2011, has raised a total of $22 million in funding over three rounds, with its latest Series B funding in July 2022. Key investors include Fresenius Medical Care and the Pritzker Vlock Family Office. - The company has a distribution partnership with Medtronic plc for its bedside Argos® Cardiac Output Monitor in the United States, which is based on the same algorithmic foundation as the new Argos Infinity™ software. - The platform's ability to provide early warnings for conditions like acute kidney injury (AKI) is significant, as AKI is now included as a hospital harm measure tied to CMS reimbursement, which will affect payments starting in 2027.